Deakin University
Browse

File(s) under permanent embargo

Regulation of glucose kinetics during intense exercise in humans: effects of α- and β-adrenergic blockade

journal contribution
posted on 2003-12-01, 00:00 authored by Kirsten HowlettKirsten Howlett, Matthew Watt, Mark Hargreaves, M Febbraio
This study examined the effect of combined α- and β-adrenergic blockade on glucose kinetics during intense exercise. Six endurance-trained men exercised for 20 minutes at approximately 78% of their peak oxygen consumption (VO 2) following ingestion of a placebo (CON) or combined α- (prazosin hydrochloride) and β- (timolol maleate) adrenoceptor antagonists (BLK). Plasma glucose increased during exercise in CON (0 minutes: 5.5 ± 0.1; 20 minutes: 6.5 ± 0.3 mmol · L−1, P < .05). In BLK, the exercise-induced increase in plasma glucose was abolished (0 minutes: 5.7 ± 0.3; 20 minutes: 5.7 ± 0.1 mmol · L−1). Glucose kinetics were measured using a primed, continuous infusion of [6,6-2H] glucose. Glucose production was not different between trials; on average these values were 25.3 ± 3.9 and 30.9 ± 4.4 μmol · kg−1 · min−1 in CON and BLK, respectively. Glucose uptake during exercise was greater (P < .05) in BLK (30.6 ± 4.6 μmol · kg−1 · min−1) compared with CON (18.4 ± 2.5 μmol · kg−1 · min−1). In BLK, plasma insulin and catecholamines were higher (P < .05), while plasma glucagon was unchanged from CON. Free fatty acids (FFA) and glycerol were lower (P < .05) in BLK. These findings demonstrate that adrenergic blockade during intense exercise results in a blunted plasma glucose response that is due to enhanced glucose uptake, with no significant change in glucose production.

History

Journal

Metabolism, clinical and experimental

Volume

52

Issue

12

Pagination

1615 - 1620

Publisher

W B Saunders Co

Location

Philadelphia, Pa.

ISSN

0026-0495

eISSN

1532-8600

Language

eng

Notes

Available online 27 November 2003.

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2003, Elsevier Inc.